Spiegel, Robert and Elliott Stupak, Jan. 9, 1987
Scope and Contents
Institution: Schering-Plough. Topics: Interferon development; difference between working at Schering and NIH; FDA drug approval process, regulatory environment for risk-taking corporate industry; forecasting future applications for Inteferon, monoclonal antibodies; Schering's anti-cancer drug program, lymphokines; migration of young scientists from NIH to industry instead of academia; technicalities of production and patenting and speed to market... competition; comparisons with Hoffman-La Roche; importance and quality of Schering's research operations; AIDS drug research, AZT, collaborations with NIH; history and development of alpha interferons, Spiegel/Stupak partnership, management tensions; competition between industry, NIH, academia
See moreDates
- Creation: Jan. 9, 1987
Scope and Contents
Institution: Schering-Plough. Topics: Interferon development; difference between working at Schering and NIH; FDA drug approval process, regulatory environment for risk-taking corporate industry; forecasting future applications for Inteferon, monoclonal antibodies; Schering's anti-cancer drug program, lymphokines; migration of young scientists from NIH to industry instead of academia; technicalities of production and patenting and speed to market... competition; comparisons with Hoffman-La Roche; importance and quality of Schering's research operations; AIDS drug research, AZT, collaborations with NIH; history and development of alpha interferons, Spiegel/Stupak partnership, management tensions; competition between industry, NIH, academia
See moreCollecting Area Details
Part of the Archives and Modern Manuscripts Collections Collecting Area
8600 Rockville Pike
Bldg 38/1E-21, MSC 3819
Bethesda MD 20894 US
1-888-FINDNLM (1-888-346-3656)
nlm-support@nlm.nih.gov